Evidence map›Paper›PMID 22745670›Full record

ArticlePloS one2012

CC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitals.

J Natalia Jiménez, Ana M Ocampo, Johanna M Vanegas, Erika A Rodriguez, José R Mediavilla, Liang Chen, Carlos E Muskus, Lázaro A Vélez, Carlos Rojas, Andrea V Restrepo and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Community-genotype methicillin-resistant Staphylococcus aureus skin and soft tissue infections in Latin America: a systematic review.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Pooled it
  2. Article
  3. Methicillin-resistantCurrent pharmaceutical biotechnology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Genotypic Characterization of Clinical Isolates ofPathogens (Basel, Switzerland) · 2021
    Article
  12. Article
  13. Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2020
    Review
  14. Control of Methicillin-ResistantFrontiers in microbiology · 2020
    Article
  15. Methicillin-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019
    Article
  16. Observational
  17. Article
  18. Detection of diverse genotypes of Methicillin-resistantAntimicrobial resistance and infection control · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

J Natalia JiménezGrupo de Microbiología Molecular, Escuela de Microbiología, Universidad de Antioquia, Medellín, Colombia. judynatalia@yahoo.com
Ana M Ocampo
Johanna M Vanegas
Erika A Rodriguez
José R Mediavilla
Liang Chen
Carlos E Muskus
Lázaro A Vélez
Carlos Rojas
Andrea V Restrepo
Sigifredo Ospina
Carlos Garcés
Liliana Franco
Pablo Bifani
Barry N Kreiswirth
Margarita M Correa
Universidad de Antioquia · COHospital Universitario de San Vicente Fundación · COClínica Santa María · COHospital Pablo Tobon Uribe · COInstitut Scientifique de Santé Publique · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent reports highlight the incursion of community-associated MRSA within healthcare settings. However, knowledge of this phenomenon remains limited in Latin America. The aim of this study was to evaluate the molecular epidemiology of MRSA in three tertiary-care hospitals in Medellín, Colombia.

methodsAn observational cross-sectional study was conducted from 2008-2010. MRSA infections were classified as either community-associated (CA-MRSA) or healthcare-associated (HA-MRSA), with HA-MRSA further classified as hospital-onset (HAHO-MRSA) or community-onset (HACO-MRSA) according to standard epidemiological definitions established by the U.S. Centers for Disease Control and Prevention (CDC). Genotypic analysis included SCCmec typing, spa typing, PFGE and MLST.

resultsOut of 538 total MRSA isolates, 68 (12.6%) were defined as CA-MRSA, 243 (45.2%) as HACO-MRSA and 227 (42.2%) as HAHO-MRSA. The majority harbored SCCmec type IVc (306, 58.7%), followed by SCCmec type I (174, 33.4%). The prevalence of type IVc among CA-, HACO- and HAHO-MRSA isolates was 92.4%, 65.1% and 43.6%, respectively. From 2008 to 2010, the prevalence of type IVc-bearing strains increased significantly, from 50.0% to 68.2% (p = 0.004). Strains harboring SCCmec IVc were mainly associated with spa types t1610, t008 and t024 (MLST clonal complex 8), while PFGE confirmed that the t008 and t1610 strains were closely related to the USA300-0114 CA-MRSA clone. Notably, strains belonging to these three spa types exhibited high levels of tetracycline resistance (45.9%).

conclusionCC8 MRSA strains harboring SCCmec type IVc are becoming predominant in Medellín hospitals, displacing previously reported CC5 HA-MRSA clones. Based on shared characteristics including SCCmec IVc, absence of the ACME element and tetracycline resistance, the USA300-related isolates in this study are most likely related to USA300-LV, the recently-described 'Latin American variant' of USA300.

Indexed as

ColombiaElectrophoresis, Gel, Pulsed-FieldHumansMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsVirulence FactorsVirulence Factors

Identifiers

PMID22745670
PMCPMC3380008
OpenAlexW2032710678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.